Lenocta (sodium stibogluconate)

P2, N=52, Recruiting, Drugs for Neglected Diseases | Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2025 --> Jun 2025

Our study showed that the process of SSG fusion treatment of ascites and pleural effusion, the interaction between TandNK cells, MPs cells, monocytes and neutrophils was induced, and large numbers of genes were expressed, resulting in upregulation of immune response, which also approved that SSG is not only used as a protein tyrosine phosphatase inhibitor, but also it works as a protein tyrosine phosphatase inhibitor. It can also be used to regulate immune cell function, recruiting immune cells to the right place with the help of PD-1 or PD-L1 to fight cancer cells in ascites and pleural effusions in cancer patients.

P=N/A, N=280, Recruiting, University of York

P2, N=52, Not yet recruiting, Drugs for Neglected Diseases | Trial completion date: Jan 2025 --> Jul 2025 | Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Jan 2025 --> Jul 2025

Anti-CD20 antibodies, like rituximab, are broadly used to treat B cell malignancies. The killing in the presence of SSG required both antibody opsonization of the target cells, as well as disruption of CD47-SIRPα interactions. These results provide a more detailed understanding of the role of neutrophil trogocytosis in antibody-mediated destruction of B cells and clues on how to further optimize antibody therapy of B cell malignancies.

P2, N=5, Recruiting, First Affiliated Hospital of Jinan University